Results 91 to 100 of about 19,369 (169)

Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations

Heliyon
Background: Anaplastic thyroid cancer (ATC), a rare and aggressive malignancy with a poor prognosis, has shown promise with the approved dabrafenib/trametinib combination for BRAFV600E mutation.
Chiao-Ping Chen, Shu-Fu Lin, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu   +7 more
doaj   +1 more source

Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next

Photochemistry and Photobiology, Volume 102, Issue 2, Page 276-289, March/April 2026.
The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal, Durdana Muntaqua, Gagan Chhabra, Nihal Ahmad   +3 more
wiley   +1 more source

Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth

Cells
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MICs), implicated in tumorigenesis, invasion, and drug resistance, and characterized by an elevated expression of stem cell markers, including CD133.
Ryyan Alobaidi, Nusrat Islam, Toni Olkey, Yogameenakshi Haribabu, Mathew Shamo, Peter Sykora, Cynthia M. Simbulan-Rosenthal, Dean S. Rosenthal   +7 more
doaj   +1 more source

An ex vivo functional biomarker of treatment response in pediatric low-grade glioma. [PDF]

PLoS One
Artz NM, Mann B, Ebbs A, Darawsheh R, Dasari R, Adefolaju A, Bell N, Trembath D, Higgins D, Elton S, Baldwin A, Hingtgen S, Kram DE, Satterlee AB.   +13 more
europepmc   +1 more source

Placing purines in precision medicine: Targeting a metabolic reliance in <i>KRAS</i>-mutant tumors. [PDF]

iScience
De Boni L, Claridge S, Nath S, Tofani K, Stein BD, Park E, Steiner S, Elemento O, Pauli C, Hopkins BD.   +9 more
europepmc   +1 more source

High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration. [PDF]

Front Bioeng Biotechnol
Hajiali H, Cholewa-Waclaw J, Ballard J, Okur KE, Elliott R, Carragher NO, El Haj AJ.   +6 more
europepmc   +1 more source

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial. [PDF]

Acta Oncol
Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium.   +18 more
europepmc   +1 more source

MEK1/2 inhibition prevents DENV and ZIKV infection via disrupting the cytoskeletal vimentin cage required for viral replication. [PDF]

J Mol Cell Biol
Huang Y, Lu J, Cui S, Zhao S, Sun S, Jiu Y.   +5 more
europepmc   +1 more source

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS^Q61R Human Endothelial Cells. [PDF]

Pediatr Blood Cancer
Alharbi S, Wagner A, Merkle S, Pastura P, McDaniel CG, Fox D, Xu Y, Cras TDL.   +7 more
europepmc   +1 more source

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review. [PDF]

Discov Oncol
Yang L, Liu X, Zhu X, Cao B, Gu Y, Liu W.   +5 more
europepmc   +1 more source